CLINICAL ROLE -
Oncology Overview: Idelalisib in Blood Cancers
Approved indications for idelalisib include relapsed chronic lymphocytic leukemia, small lymphocytic lymphoma, and follicular B-cell non-Hodgkin lymphoma.
Read More